Modeling hepatoblastoma development with human fetal liver organoids reveals YAP1 activation is sufficient for tumorigenesis  

作　　者：Li Yang Jin Chen Jianqing Liang Yufeng Zhang Qingzhe Wang Xiaojun Ren Jinsong Wei Qianchun Gong Jiting Zhang Ning Jiang Xinhua Lin Jin Li Bing Zhao 

机构地区：[1]State Key Laboratory of Genetic Engineering,School of Life Sciences,Zhongshan Hospital,Fudan University,Shanghai 200438,China [2]bioGenous Biotechnology,Inc.,Hangzhou 311231,China [3]Obstetrics and Gynecology Hospital of Fudan University,Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases,Fudan University,Shanghai 200011,China

出　　处：《Protein & Cell》2022年第9期683-688,共6页蛋白质与细胞（英文版）

摘　　要：Dear Editor,Hepatoblastoma(HB)is a predominant hepatic neoplasm that develops in children from 0 to 4 years of age at the rate of 2.16 per 1,000,000.It originates from abnormal differentiation of hepatocyte precursors(hepatoblasts)during embryogenesis(Sumazin et al.,2017).Approximately 20%of children with HB have metastasis in lung at diagnosis,which indicates poor prognosis(Angelico et al.,2019).While surgery in combination of chemotherapy and/or metastasectomy is the most popular therapy,relapse happens in a significant portion of HB patients(Zhang et al.,2021).Therefore,novel and less aggressive therapies targeting the pathogenesis of HB should be explored to prolong patients’s disease-free survival as well as to improve their quality of life.

关 键 词：FETAL diagnosis chemotherapy 

分 类 号：R735[医药卫生—肿瘤]